Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Rheumatology
Erschienen in: Clinical Rheumatology 7/2022

30.03.2022 | COVID-19 | Original Article Zur Zeit gratis

Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis

verfasst von: Feier Wang, Yubo Ma, Shanshan Xu, Huanhuan Liu, Yuting Chen, Hui Yang, Ming Shao, Wei Xu, Jiangping Kong, Liwen Chen, Shengqian Xu, Zongwen Shuai, Faming Pan

Erschienen in: Clinical Rheumatology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

COVID-19 pandemic has already had a tremendous impact on the process of human society; the survival of mankind and the healthy living environment deterioration with the influence will last for many years. This meta-analysis aims to assess the risk of COVID-19 in patients with rheumatic diseases.

Methods

PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM) were systematically searched with no language restriction up to July 5, 2021. The pooled rates were synthesized by fixed effect model or random effect model depending on heterogeneity.

Results

A total of 83 articles were included in this meta-analysis. The incidence of COVID-19 in patient with rheumatic diseases was 0.0190 (95% CI: 0.0136-0.0252), and the hospitalization rate, intensive care unit admission rate, mechanical ventilation rate, and case fatality rate of patients with rheumatic diseases infected with COVID-19 were 0.4396 (95% CI: 0.3899-0.4898), 0.0635 (95% CI: 0.0453-0.0836), 0.0461 (95% CI: 0.0330-0.0609), and 0.0346 (95% CI: 0.0218-0.0493), respectively.

Conclusions

Our research shows that patients with rheumatic diseases have great risk of COVID-19. Differences in COVID-19 incidence, hospitalization rates, and mortality rates in regions were statistically significant. We still need to pay attention to the risk of COVID-19 in patients with rheumatic diseases.

Key Points

• Although the risk of COVID-19 in patients with rheumatic diseases has been discussed in previous meta-analysis, their research directions were inconsistent, and few studies focus on prevalence or serious outcomes of COVID-19 in patient with rheumatic diseases, while the quality of these articles was variable.
• The incidence of COVID-19 and serious clinical outcomes in patients with rheumatic diseases were still high along with differential risks in most regions.
• The use of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs did not affect the hospitalization rate and mortality in rheumatism patients with COVID-19.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention %J. JAMA 323(13):1239–1242CrossRef
3.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. J Lancet 395(10223):497–506CrossRef
4.
Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P et al (2020) Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study %J. Lancet Infect Dis 20(10):1135–1140CrossRef
5.
Liang W, Guan W, Chen R, Wang W, Li J, Xu K et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China %J. Lancet Oncol 21(3):335–337CrossRef
6.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study %J. Lancet 395(10223):507–513CrossRef
7.
8.
Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. (2021) Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv
9.
Zhao J, Huang C, Huang H, Pan JK, Zeng LF, Luo MH et al (2020) Prevalence of ankylosing spondylitis in a Chinese population: a systematic review and meta-analysis. Rheumatol Int 40(6):859–872CrossRef
10.
Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW et al (2012) Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 51(4):721–729CrossRef
11.
Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB (2007) Epidemiology of autoimmune diseases in Denmark %J. J Autoimmun 29(1):1–9CrossRef
12.
Cooper GS, Stroehla BC (2003) The epidemiology of autoimmune diseases %J. Autoimmun Rev 2(3):119–125CrossRef
13.
Shichikawa K, Inoue K, Hirota S, Maeda A, Ota H, Kimura M et al (1999) Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 58(12):751–756CrossRef
14.
Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M et al (2002) The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41(7):793–800CrossRef
15.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58(1):15–25
16.
Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment %J. Rheumatology (Oxford) 52(1):53–61CrossRef
17.
Di Franco M, Lucchino B, Spaziante M, Iannuccelli C, Valesini G, Iaiani G (2017) Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections. Int J Mol Sci 18(2):293
18.
Hsu CY, Ko CH, Wang JL, Hsu TC, Lin CY (2019) Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study %J. Arthritis Res Ther 21(1):211CrossRef
19.
Ciurea A, Papagiannoulis E, Burki K, von Loga I, Micheroli R, Moller B et al (2021) Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort %J. Ann Rheum Dis 80(2):238–241CrossRef
20.
Roux CH, Brocq O, Gerald F, Pradier C, Bailly L (2020) Impact of home confinement during the COVID-19 pandemic on medication use and disease activity in spondyloarthritis Patients %J. Arthritis Rheum 72(10):1771–1772CrossRef
21.
Costantino F, Bahier L, Tarancon LC, Leboime A, Vidal F, Bessalah L et al (2021) COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence %J. Joint Bone Spine 88(1):105095CrossRef
22.
Murray K, Quinn S, Turk M, O'Rourke A, Molloy E, O'Neill L et al (2021) COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population %J. Rheumatology (Oxford) 60(2):902–906CrossRef
23.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement %J. BMJ 339:b2535CrossRef
24.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group %J. JAMA 283(15):2008–2012CrossRef
25.
Data from the COVID-19 Global Rheumatology Alliance Global Registry. The COVID-19 Global Rheumatology Alliance Global Registry; 2021. Available at: https://​rheum-covid.​org/​. Accessed August 5, 2021
26.
Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range %J. Stat Methods Med Res 27(6):1785–1805CrossRef
27.
Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range %J. BMC Med Res Methodol 14:135CrossRef
28.
Freeman MF, Tukey JW (1950) Transformations related to the angular and the square root. Ann Math Stat 21:607–611CrossRef
29.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis %J. Stat Med 21(11):1539–1558CrossRef
30.
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses %J. BMJ 327(7414):557–560CrossRef
31.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis %J. Res Synth Methods 1(2):97–111CrossRef
32.
33.
Schreiber K, Hendricks O (2021) First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea. Lancet Rheumatol 3(10):e673–e6e5CrossRef
34.
Wang Q, Liu J, Shao R, Han X, Su C, Lu W (2021) Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. Rheumatol Int 41(5):851–861CrossRef
35.
Montero F, Martinez-Barrio J, Serrano-Benavente B, Gonzalez T, Rivera J, Molina Collada J et al (2020) Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 40(10):1593–1598CrossRef
36.
Akiyama S, Hamdeh S, Micic D, Sakuraba A (2020) Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 80:384–391
37.
Gamboa-Cardenas RV, Barzola-Cerron S, Toledo-Neira D, Reategui-Sokolova C, Pimentel-Quiroz V, Zevallos-Miranda F et al (2021) Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clin Rheumatol 40(11):4725–4734CrossRef
38.
Bakasis AD, Mavragani CP, Boki KA, Tzioufas AG, Vlachoyiannopoulos PG, Stergiou IE et al (2021) COVID-19 infection among autoimmune rheumatic disease patients: data from an observational study and literature review. J Autoimmun 123:102687CrossRef
39.
Xu C, Yi Z, Cai R, Chen R, Thong BY, Mu R (2021) Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data. Autoimmun Rev 20(4):102778CrossRef
40.
Kilian A, Chock YP, Huang IJ, Graef ER, Upton LA, Khilnani A et al (2020) Acute respiratory viral adverse events during use of antirheumatic disease therapies: a scoping review. Semin Arthritis Rheum 50(5):1191–1201CrossRef
41.
Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C (2007) Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56(12):4226–4227CrossRef
42.
Ruscitti P, Conforti A, Cipriani P, Giacomelli R, Tasso M, Costa L et al (2021) Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. Adv Rheumatol 61(1):45CrossRef
43.
Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al (2021) Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 7(1):e001464
44.
Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79(7):859–866CrossRef
45.
Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al (2021) Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis 80(8):1086–1093
46.
Santos CS, Morales CM, Alvarez ED, Castro CA, Robles AL, Sandoval TP (2020) Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 39(9):2789–2796CrossRef
47.
Forster P, Forster L, Renfrew C, Forster M (2020) Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A 117(17):9241–9243CrossRef
48.
Murugan C, Ramamoorthy S, Kuppuswamy G, Murugan RK, Sivalingam Y, Sundaramurthy A (2021) COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. Int J Biol Macromol 193(Pt B):1165–1200
49.
Nikoloski Z, Alqunaibet AM, Alfawaz RA, Almudarra SS, Herbst CH, El-Saharty S et al (2021) Covid-19 and non-communicable diseases: evidence from a systematic literature review. BMC Public Health 21(1):1068CrossRef
50.
Zhong L, Wu Y, Gao J, Zhang J, Xie Q, He H et al (2021) Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study. Ann Med 53(1):770–776CrossRef
Metadaten
Titel
Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis
verfasst von
Feier Wang
Yubo Ma
Shanshan Xu
Huanhuan Liu
Yuting Chen
Hui Yang
Ming Shao
Wei Xu
Jiangping Kong
Liwen Chen
Shengqian Xu
Zongwen Shuai
Faming Pan
Publikationsdatum
30.03.2022
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Clinical Rheumatology / Ausgabe 7/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-022-06087-1

Weitere Artikel der Ausgabe 7/2022

Clinical Rheumatology 7/2022 Zur Ausgabe

Original Article

Inactivated SARS-CoV-2 vaccine in primary Sjögren’s syndrome: humoral response, safety, and effects on disease activity

Review Article

Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis

Correction

Correction to: Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation

Original Article

Synergy of sarcopenia and vitamin D deficiency in vertebral osteoporotic fractures in rheumatoid arthritis

Correction

Correction to: Ultrasonographic evaluation of distal femoral and talar cartilage thicknesses in patients with early rheumatoid arthritis and their relationship with disease activity

Review Article

Inflammatory myopathies overlapping with systemic sclerosis: a systematic review

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise